Study to Assess the PK Profile of NanoBUP Capsules Relative to Suboxone

This study has been completed.
Sponsor:
Information provided by:
Nanotherapeutics, Inc.
ClinicalTrials.gov Identifier:
NCT01260675
First received: December 13, 2010
Last updated: February 10, 2011
Last verified: February 2011

December 13, 2010
February 10, 2011
December 2010
January 2011   (final data collection date for primary outcome measure)
pharmacokinetic profile of NanoBUP Capsules relative to Suboxone [ Time Frame: 72 hours ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01260675 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Study to Assess the PK Profile of NanoBUP Capsules Relative to Suboxone
A Study to Assess the Pharmacokinetic Profile of an Investigational Formulation of Buprenorphine HCl/Naloxone HCl 8mg/2mg Capsules Relative to the Pharmacokinetic Profile of Suboxone® (Buprenorphine HCl/Naloxone HCl 8mg/2mg Sublingual Tablets).

Phase 1 study to determine the pharmacokinetic profile of NanoBUP Capsules to Suboxone.

The pharmacokinetics of an orally administered investigational buprenorphine hydrochloride/naloxone hydrochloride 2 mg/0.5 mg capsule formulation will be studied. This is a single-dose, two period, two treatment, crossover comparative bioavailability study under fasting conditions.

Observational
Not Provided
Not Provided
Not Provided
Non-Probability Sample

healthy normal volunteers

Healthy Volunteers
Not Provided
  • NanoBUP Capsules
    Investigational Formulation of Buprenorphine HCl/Naloxone HCl 8 mg/2 mg oral capsules
  • Suboxone Sublingual Tablets
    Buprenorphine HCl/Naloxone HCl 8 mg/2 mg sublingual tablets
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
12
Not Provided
January 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subject must be a male or non-pregnant, non-breastfeeding female.
  • Subject must be between 18 and 55 years of age (inclusive).
  • Subject's Body Mass Index (BMI) must be between 18 and 30 kg/m2 (inclusive), and subject must weigh a minimum of 50 kg (110 lbs).
  • Female subjects - not surgically sterile for at least 6 months or at least 2 years postmenopausal - must agree to utilize one of the following forms of contraception, if sexually active with a male partner, from screening through completion of the study. Approved forms of contraception are abstinence, hormonal (oral, implant, transdermal, vaginal, or injection) in use at least 3 consecutive months prior to the first dose of study medication, double barrier (condom with spermicide; diaphragm with spermicide), intrauterine device (IUD), or vasectomized partner (6 months minimum since vasectomy).
  • Subject must voluntarily consent to participate in this study and provide their written informed consent prior to start of any study-specific procedures.
  • Subject is willing and able to remain in the study unit for the entire duration of the confinement period and return for any outpatient visits

Exclusion Criteria:

  • History or presence of clinically significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, metabolic, dermatologic, neurologic, oncologic, or psychiatric disease or any other condition that, in the opinion of the Investigator, would jeopardize the safety of the subject or the validity of the study results.
  • A clinically significant abnormal finding on the physical exam, medical history, ECG, or clinical laboratory results at screening.
  • History or presence of allergic or adverse response to buprenorphine, naloxone, naltrexone, opioids, or any comparable or similar products.
  • Been on a significantly abnormal diet during the 4 weeks preceding the first dose of study medication.
  • Donated blood or plasma within 30 days prior to the first dose of study medication.
  • Participated in another clinical trial within 30 days prior to the first dose of study medication.
  • Used any over-the-counter (OTC) medication, including nutritional supplements, within 7 days prior to the first dose of study medication.
  • Used any prescription medication, except hormonal contraceptive or hormonal replacement therapy, within 14 days prior to the first dose of study medication.
  • Has been treated with any known enzyme altering drugs, such as barbiturates, phenothiazines, cimetidine, carbamazepine, etc., within 30 days prior to the first dose of study medication.
  • Smoked or used tobacco products within 60 days prior to the first dose of study medication.
  • History of substance abuse or dependence (including alcohol, opioids, or intravenous drug abuse)
  • Is a female with a positive pregnancy test result.
  • A positive urine screen for drugs of abuse (amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, opiates).
  • A positive urine alcohol test at screening or a positive ethanol breath test at check-in for the study period or has consumed alcohol within 48 hours prior to screening or check-in for the study period.
  • Had a positive test for, or has been treated for hepatitis B, hepatitis C, or HIV.
Both
18 Years to 55 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01260675
2009-BUP-NT/002
No
John Abernethy, MD, Nanotherapeutics, Inc.
Nanotherapeutics, Inc.
Not Provided
Principal Investigator: Michael Natalino, MD Worldwide Clinical Trials
Nanotherapeutics, Inc.
February 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP